
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. has demonstrated a robust performance in its gene editing initiatives, achieving durable FVIII levels of 80% at the 19-month mark in non-human primate studies, indicating significant potential for its Hemophilia A treatment (MGX-001). The company's proprietary genome editing toolbox, which includes advanced systems for both small and large genetic edits, underscores its competitive positioning in the biopharmaceutical sector. With a focused pipeline targeting serious disorders and a dual strategy of in vivo gene editing and technology out-licensing for ex vivo therapies, Metagenomi is well-positioned for future growth and innovation in genetic medicine.
Bears say
Metagenomi Inc reported a net loss of $19.9 million for the second quarter of 2025, equating to $0.54 per share, indicating a substantial financial strain. The company's pipeline, while ambitious, faces significant risks including potential delays in clinical assessments and the possibility of unfavorable clinical data, particularly for key candidates like MGX-001 targeting Hemophilia A. Additionally, there are concerns related to long-term dilution risk, which could further affect investor confidence and the company's financial stability.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares